47 completed, 25 recruiting, 11 terminated, 6 active not recruiting. 106 Phase 2, 23 Phase 3, 15 Phase 1.
Follow Myositis: new trials by email Literature Review of Myositis trials Research Report on Myositis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About a Medicine Called PF-08154225 in Participants With Autoimmune Diseases PF-08154225 - Systemic Lupus Erythematosus, Rheumatoid Arthritis | Phase 1 / Phase 2 | Not yet recruiting | Pfizer | 54 | 2026-11-19 | 2026-10-01 |
| FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM) FISH OIL 500MG OMEGA-3 SOFT GEL MINIS, Placebo - Dermatomyositis (DM), Juvenile Dermatomyositis (JDM) | Phase 2 | Recruiting | National Institute of Environmental Health Sciences (NIEHS) | 3000 | 2026-11-18 | 2026-11-13 |
| Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined With Immunosuppressants in the Treatment of Refractory Autoimmune Diseases anti-CD19 CAR-T cells - Systemic Lupus Erthematosus, Systemic Sclerosis (SSc) | Phase 1 / Phase 2 | Not yet recruiting | Peking University Third Hospital | 9 | 2026-11-01 | 2026-09-23 |
| FT839 in Autoimmune Diseases FT839 - ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM) | Phase 1 / Phase 2 | Recruiting | Fate Therapeutics | 446 | 2026-10-01 | 2026-09-02 |
| A Study to Test CRT-402 in Refractory Autoimmune Disease CRT-402 - Autoimmune Diseases, Systemic Lupus Erythematosus | Phase 1 / Phase 2 | Recruiting | Myeloid Therapeutics | 34 | 2026-08-26 | 2026-10-22 |
| Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study Emapalumab - Dermatomyositis, Dermatomyositis Sine Myositis | Phase 2 | Recruiting | University of Miami | 5 | 2026-07-23 | 2026-08-25 |
| Study of NM8074 in Patients with Dermatomyositis (DM) NM8074 - Dermatomyositis | Phase 2 | Not yet recruiting | NovelMed Therapeutics | 8 | 2026-06-01 | 2025-03-25 |
| Descartes-08 in Autoantibody Myositis Descartes-08, Placebo - Antisynthetase Syndrome | Phase 2 | Recruiting | Cartesian Therapeutics | 60 | 2026-04-28 | 2026-08-17 |
| Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy Ublituximab, Placebo for Ublituximab - Autoimmune Disorders | Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 30 | 2026-04-21 | 2026-11-13 |
| TELITACICEPT IN INFLAMMATORY MYOPATHIES(TELITACICEPT-IM) Telitacicept 240mg - Inflammatory Myopathy | Phase 2 / Phase 3 | Not yet recruiting | Zhongming Qiu | 30 | 2026-02-02 | 2026-01-21 |
| Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders Descartes-08 - Childhood-onset Systemic Lupus Erythematous, ANCA-Associated Vasculitis (AAV) | Phase 1 / Phase 2 | Recruiting | Cartesian Therapeutics | 50 | 2026-01-14 | 2026-07-27 |
| A Study of AZD0120 in Autoimmune Diseases AZD0120, SOC - Systemic Sclerosis, Idiopathic Inflammatory Myopathies | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 27 | 2026-01-09 | 2026-11-10 |
| Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM) ULSC (1.5 x 10^8 cells/dose), Placebo (no cells) - Idiopathic Inflammatory Myositis (IIM), DERMATOMYOSITIS OR POLYMYOSITIS | Phase 2 / Phase 3 | Recruiting | Restem, LLC. | 40 | 2026-01-06 | 2026-04-27 |
| Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty Methotrexate, Sulfasalazine, Hydroxychloroquine - Rheumatic Disease | Phase 2 | Recruiting | NYU Langone Health | 80 | 2025-12-12 | 2026-07-09 |
| Phase 2 Trial to Evaluate the Efficacy, Safety of Allogeneic Mitochondria (PN-101) in Patients With Refractory Polymyositis or Dermatomyositis placebo, PN-101 - Polymyositis, Dermatomyositis | Phase 2 | Not yet recruiting | Paean Biotechnology Inc. | 36 | 2025-12-01 | 2025-08-14 |
| Study of Deucravacitinib for Refractory Adults With Dermatomyositis/Juvenile Dermatomyositis Deucravacitinb - Myositis, Dermatomyositis | Phase 2 | Withdrawn | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 2025-11-21 | 2025-11-24 | |
| AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases. Allogeneic NK Cells - Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs) | Phase 2 | Recruiting | Artiva Biotherapeutics, Inc. | 90 | 2025-07-09 | 2026-07-31 |
| Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases anti-CD19 CAR T cell therapy - Systemic Lupus Erthematosus, Systemic Sclerosis (SSc) | Phase 1 / Phase 2 | Recruiting | Peking University Third Hospital | 9 | 2025-07-01 | 2026-09-22 |
| Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis Ruxolitinib Topical Cream - Dermatomyositis | Phase 2 | Recruiting | The Cleveland Clinic | 15 | 2025-06-01 | 2026-10-28 |
| Ruxolitinib Treatment in Inclusion Body Myositis Ruxolitinib, Placebo - Inclusion Body Myositis, Sporadic | Phase 2 | Recruiting | Assistance Publique - Hôpitaux de Paris | 80 | 2025-05-27 | 2026-05-29 |
Showing 20 of 106. Sign in to see all of them.
Dermatomyositis (61) · Polymyositis (29) · Myositis, Inclusion Body (18) · Scleroderma, Systemic (15) · Lupus Erythematosus, Systemic (11) · Arthritis, Rheumatoid (9) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (8) · Myositis Ossificans (8) · Autoimmune Diseases (6) · Lung Diseases, Interstitial (6) · Ossification, Heterotopic (6) · Sjogren's Syndrome (6) · Arthritis, Juvenile (5) · Scleroderma, Diffuse (5)
Musculoskeletal Diseases (103) · Muscular Diseases (102) · Nervous System Diseases (98) · Neuromuscular Diseases (98) · Skin Diseases (71) · Skin and Connective Tissue Diseases (71) · Connective Tissue Diseases (67) · Polymyositis (34) · Immune System Diseases (25) · Autoimmune Diseases (18) · Pathological Conditions, Signs and Symptoms (18) · Pathologic Processes (16) · Joint Diseases (15) · Arthritis (14)
Rituximab (4) · baricitinib (4) · Abatacept (3) · Cyclophosphamide (3) · Infliximab (3) · Methotrexate (3) · bimagrumab (3) · siponimod (3) · sodium thiosulfate (3) · Cyclosporine (2) · Etanercept (2) · Interleukin 1 Receptor Antagonist Protein (2) · Interleukin-2 (2) · KZR-616 (2) · Mycophenolic Acid (2)
Novartis Pharmaceuticals (7) · Clementia Pharmaceuticals Inc. (4) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (4) · Peking University People's Hospital (4) · Assistance Publique - Hôpitaux de Paris (3) · Karolinska Institutet (3) · Pfizer (3) · Abcuro, Inc. (2) · Cartesian Therapeutics (2) · Kezar Life Sciences, Inc. (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · National Institute of Environmental Health Sciences (NIEHS) (2) · National Institute of Neurological Disorders and Stroke (NINDS) (2) · Paean Biotechnology Inc. (2) · Peking University Third Hospital (2)
United States (68) · United Kingdom (22) · France (20) · Germany (15) · Italy (15) · Spain (15) · Czechia (12) · Australia (11) · Poland (11) · China (9) · Canada (8) · Japan (8) · Netherlands (8) · South Korea (8) · Hungary (7)
Zhanguo Li (4) · Adam I Schiffenbauer, M.D. (2) · Chester V. Oddis, MD (2) · Ingrid E Lundberg, MD, PhD (2) · Rohit Aggarwal, MD (2) · Adam Raff, MD, PhD (1) · Alison Ehrlich, MD (1) · Amanda McBride, MD (1) · Amit Bar-Or, MD, FRCP (1) · Andre Thevenon, Professor (1) · Andrea Morris, MD (1)
PMID 36526263, PMID 37957586, PMID 42542380, PMID 15942915, PMID 19454532, PMID 22227955, PMID 23124935, PMID 25381300, PMID 26539981, PMID 27789240, PMID 28619061, PMID 29174792, PMID 29237618, PMID 31397289, PMID 31539061, PMID 32515349, PMID 32557665, PMID 32690797, PMID 327194, PMID 33852146, PMID 35490744, PMID 35650602, PMID 35854638, PMID 36197661, PMID 36375479, PMID 36884247, PMID 37156007, PMID 37326854, PMID 37739573, PMID 37770652, PMID 37941470, PMID 38172601, PMID 38273639, PMID 38805213, PMID 38960586, PMID 39216107, PMID 39222437, PMID 39245937, PMID 39381032, PMID 39403556, PMID 39608864, PMID 39798982, PMID 39873740, PMID 39915014, PMID 40272902, PMID 41289027, PMID 41360500, PMID 41501497, PMID 41806277, PMID 41874840
2023 (3), 2014 (2), 2016 (2), 2008 (1), 2009 (1), 2015 (1), 2018 (1), 2019 (1), K23AR055664 (1), P50AR080612 (1), P60AR047784 (1), R01AR061298 (1), R21AR066286 (1)